Addressing the tissue specificity of U5 snRNP spliceosomopathies

Area of Science:

• Molecular Biology
• Genetics
• Developmental Biology

Background:

• Splicing, essential for gene expression, is catalyzed by the spliceosome, with U5 small nuclear ribonucleoprotein (snRNP) at its core.
• Pathogenic variants in U5 snRNP core proteins lead to spliceosomopathies, a class of diseases with specific clinical manifestations.
• Examples include craniofacial malformations linked to TXNL4A/EFTUD2 variants and retinitis pigmentosa linked to PRPF8/SNRNP200 variants.

Purpose of the Study:

• To explore the molecular mechanisms underlying the specific clinical manifestations of spliceosomopathies caused by U5 snRNP variants.
• To highlight current research and propose future directions for understanding these disorders.

Main Methods:

• Review of existing research on spliceosomopathies and U5 snRNP variants.
• Discussion of cell and animal models used to study disease specificity.
• Proposal for future research avenues including iPSC-derived models, transcriptomic analysis, interactome studies, and metabolomics.

Main Results:

• Cell and animal models successfully replicate the clinical specificity observed in human spliceosomopathies.
• These models provide insights into how U5 snRNP variants lead to distinct disease phenotypes despite the spliceosome's ubiquitous role.
• The research perspective identifies key areas for future investigation.

Conclusions:

• Understanding the specificity of spliceosomopathies requires sophisticated models that can recapitulate human disease phenotypes.
• Future research integrating transcriptomics, proteomics, and metabolomics in patient-derived iPSC models holds promise for elucidating U5 snRNP variant pathogenesis.
• Investigating spliceosomal protein complexes and their interactomes can reveal novel insights into disease mechanisms.